Rome, Italy, 27 November 2024 - On 11 November, the Toumai® Laparoscopic Surgical Robot System, developed by MicroPort® MedBot™, successfully performed a combined adrenal tumor and gallbladder removal surgery in Italy. This landmark achievement marks a significant milestone in Toumai®’s expansion into the global market.
In this case, the patient presented with a complex condition involving a large tumor. Although it was the surgeon’s first time using Toumai®, the procedure was performed seamlessly. The operation involved the precise dissection of the adrenal gland and tumor, clamping the inferior adrenal artery and central vein, and the successful removal of both the adrenal gland and gallbladder. The master-slave robotic operation lasted 100 minutes with minimal blood loss. Postoperatively, the patient remained stable, with no complications reported.
The lead surgeon remarked, “We are honored to be the first European hospital to utilize the Toumai® robot. Today’s operation was a success, and we were impressed by its precision and stability. It is a sophisticated and advanced system. Additionally, Toumai®’s innovative 5G remote surgery technology, already applied in Asia and Africa, offers tremendous potential to enhance medical care in remote regions. We look forward to using Toumai® for more complex procedures to achieve exceptional outcomes for our patients.”
MicroPort® MedBot™ has pioneered cutting-edge technologies in laparoscopic surgical robotics, achieving world-class standards in product quality, advanced research, and multi-disciplinary clinical applications. Toumai® offers unique advantages, including:
Toumai® also leads in clinical applications, with over 250 successful 5G remote surgeries, boasting a 100% success rate. Its achievements include the longest remote surgery conducted over 12,000 kilometers and a cumulative transmission distance exceeding 400,000 kilometers.
Earlier this year, Toumai® received CE MDR certification, authorizing its use in urology, general surgery, thoracic surgery, and gynecological laparoscopic procedures across the European Union.
Dr. He Chao, President of MicroPort® MedBot™, stated, “The global recognition of Toumai® highlights its advanced technology and the confidence it has earned from surgeons worldwide. At MicroPort® MedBot™, we are dedicated to building strong collaborations and advancing our shared vision of making surgery simpler and more accessible for everyone.”
About MicroPort® MedBot™
Commenced its development for laparoscopic surgery robots in 2014, and officially established in Shanghai in 2015, Shanghai MicroPort MedBot (Group) Co., Ltd. ("MicroPort® MedBot™", stock code: 02252.HK), a subsidiary of MicroPort Scientific Corporation ("MicroPort®", stock code: 00853.HK), is currently the only surgical robot company in the world with businesses covering five promising subsectors of surgical robots, including endoscopy, orthopedics, vascular intervention, natural orifice surgery, and percutaneous puncture. At MicroPort® MedBot™, we are committed to meeting the growing demand for cutting-edge robotic surgery. By integrating advanced research on robotics, control algorithms, image-based navigation, and precision imaging, we provide comprehensive intelligent surgical solutions to prolong and reshape the lives of patients, lead the advancement of robotic surgery, and shape the era of intelligent surgery.
More information is available at: www.medbotsurgical.com/en